Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s11845-019-02125-1.pdf
Reference17 articles.
1. Effros RB, Fletcher CV, Gebo K et al (2008) Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 47(4):542–553
2. Vance DE, Mugavero M, Willig J et al (2011) Aging with HIV: a cross sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care 22(1):17–25
3. Shah SS, McGowan JP, Smith C, Blum S, Klein RS (2002) Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis 35(10):1238–1243
4. Gore-Felton C, Vosvick M, Power R, Koopman C, Ashton E, Bachmann MH, Israelski D, Spiegel D (2003) Alternative therapies: a common practice among men and women living with HIV. J Assoc Nurses AIDS Care 14:17–27
5. Evans-Jones JG, Cottle LE, Back DJ, Gibbons S, Beeching NJ, Carey PB, Khoo SH (2010) Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 50(10):1419–1421
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer;European Journal of Cancer;2024-05
2. A retrospective study: Can dual ART mitigate the risk of potential drug-drug interactions among PLWH under stable ART?;Turkish Journal of Medical Sciences;2023-10-26
3. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations;Medicinal Chemistry Research;2022-08-30
4. Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan;PLOS ONE;2022-06-14
5. Drug-drug interactions with OTC medicines;Therapeutic Drug Monitoring;2021-08-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3